With the start of a Phase 2 clinical trial imminent for the ARG-007 brain treatment drug, what should investors be on the look out for?

Stockhead’s Sarah Hughan sits down with Argenica Therapeutics (ASX:ASGN) CEO and managing director Dr Liz Dallimore to get the short end of the long story on the company’s latest works.

Major hospitals in WA, South Australia, VIC, NSW and QLD have all confirmed their participation in the upcoming trial with site governance due to be completed later this quarter.

Argenica’s lead neuroprotective peptide candidate ARG-007 has already successfully demonstrated improved outcomes in pre-clinical stroke models, traumatic brain injury and hypoxic ischaemic encephalopathy.

This trial marks a major milestone following a decade of work on ARG-007.

“Anyone coming into emergency departments in hospitals across Australia over the next 18 months could potentially be recruited into our trial, which is very exciting,” Dallimore told Stockhead TV.

Tune in to hear Argenica’s Dr Liz Dallimore on what to expect from the Phase 2 clinical trial, potential partnerships with other companies on the cards for Argenica and what peers there are to ARG-007 in the medical field.